Glucose Health Inc. Investor Relations Statement:
Recent postings on this forum lack reasonable context and therefore, for the consideration of shareholders and other investors interested in Glucose Health, Inc, we offer our response:
1) All debt issued by the Company's current management is FIXED price convertible debt. A minority of the Company’s total debt, issued by previous management, is not fixed price debt. No issuances of stock related to the non-fixed price debt have taken place under the Company’s current management.
2) The Company’s revenues for Q2 are entirely consistent with the Company’s stated plan of operations. The Company’s primary focus is NOT direct sales to consumers via the internet, but instead, is sales to consumers through national and regional pharmacy retailer partners. Quoting directly from page 11 of the 10-Q “Our Plan of Operation for the Next Twelve Months”:
“Our principal business strategy for the next twelve months will be to implement a marketing and sales strategy focused on securing repeat orders from national and regional pharmacy retailers for our Glucose Health® products.”
Furthermore, production of Glucose Health® was only completed near the end of the quarter on May 23rd. Even though the Company did not expend any significant funds advertising the product (consistent with its wholesale focus), sales did occur in the quarter. Additionally, please note for context, the Company achieves revenues immediately from sales to consumers via its website, but revenues from sales through wholesale channels are not immediate and only occur upon invoicing.
3) Highlights from the 10-Q:
Glucose Health, Inc. earned a Gross Profit demonstrating, even with just nominal revenues in Q-2, that sales of Glucose Health® can be achieved profitably.
Glucose Health, Inc. continues to substantially reduce operating expenses. Total corporate expenses in Q2 – 2015 were $42,588 vs. $71,346 Q-2 – 2014.
Glucose Health, inc. was awarded trademark protection from the USPTO for Glucose Health®
